Skip to content

Study · Not a test of the peptide alone · 2013

2 results

Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual.

Bergoglio MT, Gómez-Balaguer M, Almonacid Folch E, Hurtado Murillo F, Hernández-Mijares A

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion27 Sept 2012Cited by 36 (Europe PMC)

PMID23022362 (opens in a new tab)DOI10.1016/j.endonu.2012.07.004 (opens in a new tab)PepBankPUB-23022362
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    After meningioma resection and subsequent triptorelin initiation, the patient's symptoms improved at 1-year follow-up.

    In plain wordsAfter meningioma surgery and subsequent triptorelin treatment, the patient's symptoms improved at follow-up.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseSymptoms at follow-up
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    At 1-year follow-up the patient's symptoms had ameliorated and a MRI scan revealed no recurrence of the tumor.
    2 context sentences
    Summary · context
    Treatment was discontinued and tumor resection was performed.
    Summary · context
    After surgery, the patient rejected the possibility of continuing with the treatment of estrogens and cyproterone, and so triptorelin (GnRH agonist) was initiated.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    After meningioma resection and subsequent triptorelin initiation, MRI showed no tumor recurrence at 1-year follow-up.

    In plain wordsAfter meningioma surgery and subsequent triptorelin treatment, MRI showed no tumor recurrence at follow-up.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableMeningioma recurrence
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    At 1-year follow-up the patient's symptoms had ameliorated and a MRI scan revealed no recurrence of the tumor.
    2 context sentences
    Summary · context
    Treatment was discontinued and tumor resection was performed.
    Summary · context
    After surgery, the patient rejected the possibility of continuing with the treatment of estrogens and cyproterone, and so triptorelin (GnRH agonist) was initiated.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.